The nation of Zimbabwe has turned down a significant American health deal worth $367m (£272m) over five years because of the United States' request for confidential information.
This rejection became public following a internal memorandum from December was disclosed, indicating that President Emmerson Mnangagwa deemed the agreement was "lopsided".
An official representative later clarified that the United States was requesting genetic material for research and commercial purposes but was not willing to guarantee the benefits from future treatments.
"We are forced to start the difficult and regrettable task of winding down our health aid in Zimbabwe," stated US ambassador to Zimbabwe Pamela Tremont in a statement.
The US Embassy indicated the US had donated more than $1.9bn in health funding to Zimbabwe during the past twenty years.
A physicians' group in Zimbabwe has urged more talks to reach a agreement agreeable to both sides so the country's vital HIV programme can proceed.
Broader Background
Zimbabwe's decision comes after a similar case in neighbouring Kenya, where a court blocked a related deal with the US following concerns were raised about the safety of Kenyans' medical information.
Since resuming office last year, US President Donald Trump has reduced overseas assistance and shut down the key foreign aid agency.
USAID had administered assistance for the American government, but Trump claimed its expenditure was "inefficient" and his government was pursuing government-to-government agreements to boost transparency and responsibility.
Based on statements, 16 nations in Africa have so far agreed to similar agreements, representing over $18.3bn in new funding.
Specifics of the Rejected Agreement
The money for Zimbabwe would have gone towards "tackling HIV/Aids, TB, malaria, maternal and child health, and preparing for epidemics".
"We believe this collaboration would have delivered extraordinary benefits for the people of Zimbabwe, particularly the 1.2 million presently receiving HIV treatment via US-supported programmes," Tremont said.
However, official spokesman Nick Mangwana said the proposed deal was "unequal".
"The proposal required Zimbabwe to surrender its biological resources and data indefinitely, with no corresponding guarantee of benefiting from any scientific breakthroughs – such as vaccines, diagnostics, or treatments – that could be developed from that shared data," his statement read.
"In essence, our country would provide the raw materials for medical research with no assurance that the final treatments would be accessible to our people should a new disease outbreak emerge."
Sovereignty and International Frameworks
Mangwana further pointed out that the American exit from the World Health Organization (WHO) and its push of bilateral health agreements were undermining frameworks already set up through the global organization.
Mangwana cited its Pathogen Access and Benefit Sharing system created to manage potential global health emergencies.
"This framework is intended to ensure that when a country contributes its samples, the resulting advantages – including vaccines and treatments – are shared equitably, not commercialised solely by those with the resources to create them."
Zimbabwe's reservations over the US deal "must not be interpreted as opposition to America," he added.
"We are open to ongoing dialogue with our American counterparts on how future collaboration might be designed in a manner that honours the independence and dignity of both nations."
Health Experts Reaction
The Zimbabwe College of Public Health Physicians (ZCPHP) expressed it understood the official position, but urged that talks need to persist considering much of the country's Aids initiatives were funded by foreign aid.
"If technical issues arise, including those relating to data governance or agreement terms, these can frequently be addressed via detailed discussion and negotiated safeguards," it said.
The halted deal emphasises the continuing challenges between receiving vital foreign assistance and protecting a country's data in an increasingly data-driven world.